Subscribe to our Newsletters !!
The safety and quality of produced medicines is ex
In the current technologically-driven Pharma and b
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Can gene editing be used as a life-saving treatmen
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-look
Roche drug Hemlibra has a good chance to become the first choice of treatment for the patients who are suffering from Hemopilia.Basically, Hemlibra is a humanized monoclonal antibody drug for the treatment of haemophilia which is given through an injection, it was observed that it reduces the bleed dramatically in hemphilia tests.
At the world Federation of Hemophilia’s world congress in Scotland,Roche’s-Genentech unit disclosed the details from the twophases 3 studies on emicizumab. The trails were termed as HEAVEN-3 & HEAVEN-4.
At the world Federation of Hemophilia’s world congress in Scotland,Roche’s-Genentech unit disclosed the details from the twophases 3 studies on emicizumab. The trails were termed as HEAVEN-3 & HEAVEN-4..
It was reported that Hemlibra was able to cut down 96% of the bleeds in Hemophilia. Some comparisons were observed between a patient who didn’t received preventive treatment whereas a patient who received the preventive treatment in the form of clotting factors it reduces them by 68%.
The firm will submit the new data to regulators in the U.S. and Europe for approval.
